BPC-157 · research summary

Stable Gastric Pentadecapeptide BPC 157 as a Therapy and Safety Key: A Special Beneficial Pleiotropic Effect Controlling and Modulating Angiogenesis and the NO-System.

Pharmaceuticals (Basel, Switzerland) · 2025. Summary drawn from the study's full text. Each statement is followed by the exact sentence it comes from. This is a research summary, not medical advice.

Study type

Review article summarizing existing literature on BPC 157
“Therefore, this review, summarizing the issue already largely reviewed [1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40], highlights key advantages of BPC 157’s (Body Protection Compound, GEPPPGKPADDAGLV, M.W. 1419, partial sequence of human gastric juice protein BPC, also known as BPC-157, BPC157, BPC 15, PL-10, PL-14736, and bepecin) beneficial pleiotropic effects.”

Subjects

Rats, mice, albino rabbits, and human cell lines
“In toxicology studies, BPC 157 exhibited a negative limit test, 2 g/kg i.v. or i.g., without adverse effects in mice, and a lethal dose (LD1) was not achieved [3,4,5,6,7,8,9,10,11,12,13,14,16,17,18,19,20,21,22,23,24,27,28,29,30,31,32,34,37,39,40].”

Duration

Varies by specific study, with examples including 8-week studies and treatments up to 120 hours
“Contrarily, in bile duct occluded rats, in an 8-week study [118], BPC 157 was given continuously (intraperitoneally once a day or perorally (continuously in drinking water)) or only once as a direct bath application.”

Reported findings

BPC 157 promotes wound healing and tissue integrity in various organs, including the stomach, cornea, tendons, and muscles.
“BPC 157 resolved cornea transparency maintenance, cornea healing “angiogenic privilege” (vs. angiogenesis/neovascularization/tumorigenesis), and it does not produce corneal neovascularization but rather opposes it.”
BPC 157 exhibits anti-tumor potential by inhibiting VEGF signaling and reducing metastasis in animal models.
“BPC 157 counteracts the VEGF tumor-promoting effect and inhibits cell growth and VEGF signaling via the MAPK kinase pathway in the human melanoma cell line [95].”
BPC 157 modulates the nitric oxide (NO) system, counteracting both NO inhibition and over-stimulation, and shows effects in neurodegenerative disease models.
“in mice and rats, BPC 157 therapy counteracts Parkinson’s disease-like and Alzheimer’s disease-like disturbances.”

Limitations stated by the authors

The text is a review of previous studies rather than a primary experimental study, and specific sample sizes for individual cited experiments are not detailed in this text.
“Therefore, this review, summarizing the issue already largely reviewed [1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40], highlights key advantages of BPC 157’s (Body Protection Compound, GEPPPGKPADDAGLV, M.W. 1419, partial sequence of human gastric juice protein BPC, also known as BPC-157, BPC157, BPC 15, PL-10, PL-14736, and bepecin) beneficial pleiotropic effects.”

Source: PubMed 40573323 · DOI 10.3390/ph18060928 · all study summaries

Study type

Review article summarizing existing literature on BPC 157

“Therefore, this review, summarizing the issue already largely reviewed [1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40], highlights key advantages of BPC 157’s (Body Protection Compound, GEPPPGKPADDAGLV, M.W. 1419, partial sequence of human gastric juice protein BPC, also known as BPC-157, BPC157, BPC 15, PL-10, PL-14736, and bepecin) beneficial pleiotropic effects.”

Subjects

Rats, mice, albino rabbits, and human cell lines

“In toxicology studies, BPC 157 exhibited a negative limit test, 2 g/kg i.v. or i.g., without adverse effects in mice, and a lethal dose (LD1) was not achieved [3,4,5,6,7,8,9,10,11,12,13,14,16,17,18,19,20,21,22,23,24,27,28,29,30,31,32,34,37,39,40].”

Duration

Varies by specific study, with examples including 8-week studies and treatments up to 120 hours

“Contrarily, in bile duct occluded rats, in an 8-week study [118], BPC 157 was given continuously (intraperitoneally once a day or perorally (continuously in drinking water)) or only once as a direct bath application.”

Reported findings

BPC 157 promotes wound healing and tissue integrity in various organs, including the stomach, cornea, tendons, and muscles.

“BPC 157 resolved cornea transparency maintenance, cornea healing “angiogenic privilege” (vs. angiogenesis/neovascularization/tumorigenesis), and it does not produce corneal neovascularization but rather opposes it.”

BPC 157 exhibits anti-tumor potential by inhibiting VEGF signaling and reducing metastasis in animal models.

“BPC 157 counteracts the VEGF tumor-promoting effect and inhibits cell growth and VEGF signaling via the MAPK kinase pathway in the human melanoma cell line [95].”

BPC 157 modulates the nitric oxide (NO) system, counteracting both NO inhibition and over-stimulation, and shows effects in neurodegenerative disease models.

“in mice and rats, BPC 157 therapy counteracts Parkinson’s disease-like and Alzheimer’s disease-like disturbances.”

Limitations stated by the authors

The text is a review of previous studies rather than a primary experimental study, and specific sample sizes for individual cited experiments are not detailed in this text.

“Therefore, this review, summarizing the issue already largely reviewed [1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40], highlights key advantages of BPC 157’s (Body Protection Compound, GEPPPGKPADDAGLV, M.W. 1419, partial sequence of human gastric juice protein BPC, also known as BPC-157, BPC157, BPC 15, PL-10, PL-14736, and bepecin) beneficial pleiotropic effects.”